Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AF-219 in Chronic Cough
2010-024283-18Phase 2Completed
- Sponsor
- Afferent Pharmaceuticals, Inc.
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gefapixant in chronic cough (2 arms), sponsored by Afferent Pharmaceuticals, Inc. Primary endpoint: Daytime objective cough frequency reduction after 2 weeks of AF-219. Started Feb 2011; status: completed.
02
Drugs
gefapixant
03
Conditions
chronic cough
Beyond the preview
Go deeper on 2010-024283-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024283-18.